The ink on FDA's controversial approval of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug Exondys 51 has not been dry long, yet other sponsors already want to employ the company's development model.
The emerging trend worries Peter Kolchinsky, managing director of RA Capital Management, who said some companies believe that there is...






